Fennec Pharmaceuticals Inc. (FENC) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

18/25

Growth 4 Margin 4 Expansion 3 Platform 3 Financial 4

latest quarter score

Earnings Reports

18
Fennec Pharmaceuticals (FENC) Q2 2026: 78% Revenue Surge Highlights Commercial Expansion and Clinical Momentum
August 11, 2026
20
Fennec (FENC) Q1 2026: PEDMARK Sales Surge 73% as Commercial Expansion Unlocks New Patient Access
May 14, 2026
18
FENIC Pharmaceuticals (FENC) Q4 2025: PEDMARK Conversion Rate Jumps to 70% as AYA Expansion Accelerates
March 24, 2026
15
Fennec Pharmaceuticals (FENC) Q2 2025: PEDMARK Drives 33% Growth as AYA Adoption Accelerates
August 14, 2025
11
Fennec Pharmaceuticals (FENC) Q1 2025: 18% Sales Growth Validates Focused Commercial Strategy
May 13, 2025
14
Fennec Pharmaceuticals (FENC) Q4 2024: 40% Annual PEDMARK Sales Growth Signals Expansion into AYA Segment
March 10, 2025

Browse all companies